|
Volumn 68, Issue 16, 2007, Pages 1245-1246
|
What's the problem with generic antiepileptic drugs? A call to action
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICONVULSIVE AGENT;
GENERIC DRUG;
ZONISAMIDE;
AREA UNDER THE CURVE;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG MARKETING;
DRUG SURVEILLANCE PROGRAM;
EDITORIAL;
EPILEPSY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MEDICAL LITERATURE;
PRIORITY JOURNAL;
UNSPECIFIED SIDE EFFECT;
ANTICONVULSANTS;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUGS, GENERIC;
EPILEPSY;
HUMANS;
PRODUCT SURVEILLANCE, POSTMARKETING;
RECURRENCE;
RISK ASSESSMENT;
THERAPEUTIC EQUIVALENCY;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 34247223819
PISSN: 00283878
EISSN: None
Source Type: Journal
DOI: 10.1212/01.wnl.0000262876.37269.8b Document Type: Editorial |
Times cited : (43)
|
References (9)
|